HALOZYME THERAPEUTICS
Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and di... spersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need.
HALOZYME THERAPEUTICS
Industry:
Biotechnology Marketing Medical
Founded:
1998-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.halozyme.com
Total Employee:
101+
Status:
Active
Contact:
858.794.8889
Total Funding:
245 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Tag Manager WordPress Wordpress Plugins Organization Schema IPv6 ReCAPTCHA Cloudflare JS
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Dice Therapeutics
Dice Therapeutics develops a transformative platform designed for the discovery of novel small molecules.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company that discovers and develops precise medicines for human disease.
Current Advisors List
Board_member
Board_member
Current Employees Featured
Ben Hickey Chief Financial Officer @ Halozyme Therapeutics
Chief Financial Officer
2022-02-01
Mas Matsuda Chief Compliance Officer @ Halozyme Therapeutics
Chief Compliance Officer
Becky Tanamachi Executive Director @ Halozyme Therapeutics
Executive Director
Daniel Sauder Senior Consultant @ Halozyme Therapeutics
Senior Consultant
2009-01-01
Michael J LaBarre Chief Technical Officer @ Halozyme Therapeutics
Chief Technical Officer
Elaine Sun SVP and Chief Financial Officer @ Halozyme Therapeutics
SVP and Chief Financial Officer
2020-02-01
Kurt Gustafson Vice President, CFO @ Halozyme Therapeutics
Vice President, CFO
Steve Knowles Chief Medical Officer @ Halozyme Therapeutics
Chief Medical Officer
Helen Torley Chief Executive Officer, President @ Halozyme Therapeutics
Chief Executive Officer, President
Jake Beverage Senior Director, Alliance and Program Management @ Halozyme Therapeutics
Senior Director, Alliance and Program Management
2019-12-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-04-13 | Antares Pharma | Antares Pharma acquired by Halozyme Therapeutics | 960 M USD |
Investors List
Janssen Biotech
Janssen Biotech investment in Post-IPO Equity - Halozyme Therapeutics
arGEN-X
arGEN-X investment in Post-IPO Equity - Halozyme Therapeutics
Pharmakon Advisors
Pharmakon Advisors investment in Post-IPO Debt - Halozyme Therapeutics
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - Halozyme Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Halozyme Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Halozyme Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Halozyme Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Halozyme Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-02 | Halozyme Appoints New Chief Financial Officer |
| 2020-02-24 | Halozyme Announces CFO Transition |
Official Site Inspections
http://www.halozyme.com Semrush global rank: 3.28 M Semrush visits lastest month: 5 K
- Host name: 104-237-144-180.ip.linodeusercontent.com
- IP address: 104.237.144.180
- Location: Newark United States
- Latitude: 40.739
- Longitude: -74.1697
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07175
More informations about "Halozyme Therapeutics"
Halozyme - Wikipedia
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. See details»
Reinventing the patient experience. | Halozyme
The patient is at the forefront of everything we do at Halozyme. With our disruptive drug delivery technologies and robust commercial portfolio, we are committed to reinventing the patient …See details»
Halozyme Therapeutics - Crunchbase Company Profile …
Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, …See details»
Responsibility - Halozyme
Halozyme has established a compliance reporting mechanism intended to supplement, not replace, other channels for communicating questions or concerns within the organization. A company independent of Halozyme staffs …See details»
Halozyme Therapeutics, Inc. - Investor Relations
Feb 4, 2025 Contact Us. Tram Bui Vice President, Investor Relations & Corporate Communications 609-359-3016 tbui@halozyme.com media@halozyme.com ir@halozyme.comSee details»
Halozyme, Inc. - LinkedIn
Halozyme, Inc. | 20,111 followers on LinkedIn. At Halozyme we continuously push the pace of innovation. | Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly ...See details»
Halozyme Therapeutics - The Org
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Industries. …See details»
Halozyme Therapeutics - Leadership Team - The Org
The Leadership Team at Halozyme Therapeutics is responsible for steering the company's strategic vision and making high-level decisions to drive innovation in biopharmaceuticals. …See details»
About HALOZYME THERAPEUTICS, INC. | DxMultiomics
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators …See details»
Halozyme Therapeutics, Inc. (HALO) - Yahoo Finance Canada
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. …See details»
Halozyme Announces Bristol Myers Squibb Received Positive …
18 hours ago Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received a positive opinion from the Committee for Medicinal Products …See details»
Halozyme Therapeutics, Inc. - Events & Presentations - Presentations
Jan 8, 2025 Contact Us. Tram Bui Vice President, Investor Relations & Corporate Communications 609-359-3016 tbui@halozyme.com media@halozyme.com ir@halozyme.comSee details»
Halozyme Therapeutics Inc - Company Profile - GlobalData
Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes for enhancing the delivery of biologics …See details»
BIO: In conversation with Helen Torley, CEO of Halozyme
Jun 7, 2019 Halozyme’s lead program is a treatment for pancreatic cancer combining PEGPH20, a PEGylated version of the company’s hyaluronidase enzyme, with Celgene’s …See details»
Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion …
16 hours ago (RTTNews) - Halozyme Therapeutics, Inc. (HALO), Monday announced that Bristol Myers Squibb (BMY) received a positive opinion from the Committee for Medicinal Products …See details»
Environmental, Social & Governance Report - Halozyme
Organization. Halozyme’s SASB table, which can be found in this report, provides an ESG guidance framework setting industry standards for the disclosure of financially material …See details»
Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10, 2024 Halozyme's (NASDAQ:HALO) ENHANZE technology, which facilitates "rapid high-dose, high-volume subcutaneous drug delivery," has transformed the company into a …See details»
HALOZYME ANNOUNCES $750 MILLION THREE-YEAR SHARE …
SAN DIEGO, Dec. 9, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its Board of Directors has approved a new share repurchase program effective …See details»
Insights Value Series: Introduction | Halozyme
We want to provide some insight into our company’s values in an ongoing series on Halozyme’s Insights webpage. This series is an opportunity to continue to build our connectivity and …See details»
ViiV Healthcare and Halozyme enter global collaboration and …
London and San Diego, 22 June 2021 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as …See details»